These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 35574502)
1. Covaxin: An overview of its immunogenicity and safety trials in India. Sharma R; Tiwari S; Dixit A Bioinformation; 2021; 17(10):840-845. PubMed ID: 35574502 [TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Ella R; Reddy S; Jogdand H; Sarangi V; Ganneru B; Prasad S; Das D; Raju D; Praturi U; Sapkal G; Yadav P; Reddy P; Verma S; Singh C; Redkar SV; Gillurkar CS; Kushwaha JS; Mohapatra S; Bhate A; Rai S; Panda S; Abraham P; Gupta N; Ella K; Bhargava B; Vadrevu KM Lancet Infect Dis; 2021 Jul; 21(7):950-961. PubMed ID: 33705727 [TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Ella R; Vadrevu KM; Jogdand H; Prasad S; Reddy S; Sarangi V; Ganneru B; Sapkal G; Yadav P; Abraham P; Panda S; Gupta N; Reddy P; Verma S; Kumar Rai S; Singh C; Redkar SV; Gillurkar CS; Kushwaha JS; Mohapatra S; Rao V; Guleria R; Ella K; Bhargava B Lancet Infect Dis; 2021 May; 21(5):637-646. PubMed ID: 33485468 [TBL] [Abstract][Full Text] [Related]
4. Inactivated vaccine Covaxin/BBV152: A systematic review. Ahmed TI; Rishi S; Irshad S; Aggarwal J; Happa K; Mansoor S Front Immunol; 2022; 13():863162. PubMed ID: 36016940 [TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152). Sunagar R; Prasad SD; Ella R; Vadrevu KM Front Immunol; 2022; 13():1063679. PubMed ID: 36569867 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study. Vadrevu KM; Reddy S; Jogdand H; Ganneru B; Mirza N; Tripathy VN; Singh C; Khalatkar V; Prasanth S; Rai S; Ella R; Blackwelder W; Prasad S; Ella K Lancet Infect Dis; 2022 Sep; 22(9):1303-1312. PubMed ID: 35717995 [TBL] [Abstract][Full Text] [Related]
7. A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects. Dotiwala F; Upadhyay AK Front Immunol; 2022; 13():940715. PubMed ID: 36177016 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study. Desai D; Khan AR; Soneja M; Mittal A; Naik S; Kodan P; Mandal A; Maher GT; Kumar R; Agarwal A; Gowda NR; H V; Kumar P; Pandey S; Pandey RM; Kumar A; Ray A; Jorwal P; Nischal N; Choudhary A; Brijwal M; Madan K; Lodha R; Sinha S; Dar L; Wig N; Guleria R Lancet Infect Dis; 2022 Mar; 22(3):349-356. PubMed ID: 34826383 [TBL] [Abstract][Full Text] [Related]
12. Characterization of immune responses to two and three doses of the adenoviral vectored vaccine ChAdOx1 nCov-19 and the whole virion inactivated vaccine BBV152 in a mix-and-match study in India. Chaudhary A; Madhavan R; Babji S; Raju R; Syed C; Kumar A; Saravanan P; Sharon Nikitha O; Leander Xavier JV; David Chelladurai JS; Deborah AA; George A; Kang G; Rose W Vaccine; 2023 Jul; 41(33):4808-4822. PubMed ID: 37357073 [TBL] [Abstract][Full Text] [Related]
13. Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation. Ganneru B; Jogdand H; Daram VK; Das D; Molugu NR; Prasad SD; Kannappa SV; Ella KM; Ravikrishnan R; Awasthi A; Jose J; Rao P; Kumar D; Ella R; Abraham P; Yadav PD; Sapkal GN; Shete-Aich A; Desphande G; Mohandas S; Basu A; Gupta N; Vadrevu KM iScience; 2021 Apr; 24(4):102298. PubMed ID: 33723528 [TBL] [Abstract][Full Text] [Related]
14. Inactivated COVID-19 vaccines: durability of Covaxin/BBV152 induced immunity against variants of concern. Kumar NP; Banurekha VV; Kumar CPG; Nancy A; Padmapriyadarsini C; Shankar S; Hanna LE; Murhekar M; Devi KRU; Babu S J Travel Med; 2022 Sep; 29(6):. PubMed ID: 35900009 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study. Bhatnagar T; Chaudhuri S; Ponnaiah M; Yadav PD; Sabarinathan R; Sahay RR; Ahmed F; Aswathy S; Bhardwaj P; Bilimale A; Kumar MS; Logaraj M; Narlawar U; Palanivel C; Patel P; Rai SK; Saxena V; Singh A; Thangaraj JW; Agarwal A; Alvi Y; Amoghashree ; Ashok P; Babu D; Bahurupi Y; Bhalavi S; Behera P; Biswas PP; Charan J; Chauhan NK; Chetak KB; Dar L; Das A; Deepashree R; Dhar M; Dhodapkar R; Dipu TS; Dudeja M; Dudhmal M; Gadepalli R; Garg MK; Gayathri AV; Goel AD; Gowdappa HB; Guleria R; Gupta MK; Islam F; Jain M; Jain V; Jawahar MLS; Joshi R; Kant S; Kar SS; Kalita D; Khapre M; Khichar S; Kombade SP; Kohli S; Kumar A; Kumar A; Kumar D; Kulirankal KG; Leela KV; Majumdar T; Mishra B; Misra P; Misra S; Mohapatra PR; Murthy MN; Nyayanit DA; Patel M; Pathania M; Patil S; Patro BK; Jalandra R; Rathod P; Shah N; Shete A; Shukla D; Shwethashree M; Sinha S; Sumana MN; Surana A; Trikha A; Tejashree A; Venkateshan M; Vijaykrishnan G; Wadhava S; Wig N; Gupta N; Abraham P; Murhekar MV Int J Infect Dis; 2022 Sep; 122():693-702. PubMed ID: 35843496 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin. Kant R; Dwivedi G; Zaman K; Sahay RR; Sapkal G; Kaushal H; Nyayanit DA; Yadav PD; Deshpande G; Singh R; Chaowdhary S; Gupta N; Kumar S; Abraham P; Panda S; Bhargava B J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34652440 [TBL] [Abstract][Full Text] [Related]
17. Media Reporting Relating to COVID-19 Vaccination as a Driver of Vaccine Hesitancy Prior to the Second Wave of the COVID-19 Pandemic in India: A Content Analysis of Newspaper and Digital Media Reports. Basu S; Sharma H Cureus; 2023 Mar; 15(3):e36750. PubMed ID: 37123709 [TBL] [Abstract][Full Text] [Related]
18. Antibody responses to the BBV152 vaccine in individuals previously infected with SARS-CoV-2: A pilot study. Kumar NP; Padmapriyadarsini C; Uma Devi KR; Banurekha VV; Nancy A; Girish Kumar CP; Murhekar MV; Gupta N; Panda S; Babu S; Bhargava B Indian J Med Res; 2021 May; 153(5&6):671-676. PubMed ID: 34528524 [TBL] [Abstract][Full Text] [Related]
19. Comparison of Biological, Pharmacological Characteristics, Indications, Contraindications, Efficacy, and Adverse Effects of Inactivated Whole-Virus COVID-19 Vaccines Sinopharm, CoronaVac, and Covaxin: An Observational Study. Meo SA; ElToukhy RA; Meo AS; Klonoff DC Vaccines (Basel); 2023 Apr; 11(4):. PubMed ID: 37112738 [TBL] [Abstract][Full Text] [Related]
20. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. Xia S; Duan K; Zhang Y; Zhao D; Zhang H; Xie Z; Li X; Peng C; Zhang Y; Zhang W; Yang Y; Chen W; Gao X; You W; Wang X; Wang Z; Shi Z; Wang Y; Yang X; Zhang L; Huang L; Wang Q; Lu J; Yang Y; Guo J; Zhou W; Wan X; Wu C; Wang W; Huang S; Du J; Meng Z; Pan A; Yuan Z; Shen S; Guo W; Yang X JAMA; 2020 Sep; 324(10):951-960. PubMed ID: 32789505 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]